168 related articles for article (PubMed ID: 16230379)
1. Ku86 modulates DNA topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells.
Shih SJ; Erbele T; Chen AY
Cancer Res; 2005 Oct; 65(20):9194-9. PubMed ID: 16230379
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the DNA replication competence of the xrs-5 mutant cells defective in Ku86.
Matheos D; Novac O; Price GB; Zannis-Hadjopoulos M
J Cell Sci; 2003 Jan; 116(Pt 1):111-24. PubMed ID: 12456721
[TBL] [Abstract][Full Text] [Related]
3. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Holm C; Covey JM; Kerrigan D; Pommier Y
Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
[TBL] [Abstract][Full Text] [Related]
4. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives.
Chen AY; Okunieff P; Pommier Y; Mitchell JB
Cancer Res; 1997 Apr; 57(8):1529-36. PubMed ID: 9108456
[TBL] [Abstract][Full Text] [Related]
5. Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.
Chen AY; Shih SJ; Garriques LN; Rothenberg ML; Hsiao M; Curran DP
Mol Cancer Ther; 2005 Feb; 4(2):317-24. PubMed ID: 15713902
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity of Ku-deficient cells toward the DNA topoisomerase II inhibitor ICRF-193 suggests a novel role for Ku antigen during the G2 and M phases of the cell cycle.
Muñoz P; Zdzienicka MZ; Blanchard JM; Piette J
Mol Cell Biol; 1998 Oct; 18(10):5797-808. PubMed ID: 9742097
[TBL] [Abstract][Full Text] [Related]
7. Effect of Ku86 and DNA-PKcs deficiency on non-homologous end-joining and homologous recombination using a transient transfection assay.
Secretan MB; Scuric Z; Oshima J; Bishop AJ; Howlett NG; Yau D; Schiestl RH
Mutat Res; 2004 Oct; 554(1-2):351-64. PubMed ID: 15450431
[TBL] [Abstract][Full Text] [Related]
8. Examining the non-homologous repair process following cisplatin and radiation treatments.
Myint WK; Ng C; Raaphorst GP
Int J Radiat Biol; 2002 May; 78(5):417-24. PubMed ID: 12020431
[TBL] [Abstract][Full Text] [Related]
9. An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents.
Belenkov AI; Paiement JP; Panasci LC; Monia BP; Chow TY
Cancer Res; 2002 Oct; 62(20):5888-96. PubMed ID: 12384553
[TBL] [Abstract][Full Text] [Related]
10. Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants.
Errami A; Smider V; Rathmell WK; He DM; Hendrickson EA; Zdzienicka MZ; Chu G
Mol Cell Biol; 1996 Apr; 16(4):1519-26. PubMed ID: 8657125
[TBL] [Abstract][Full Text] [Related]
11. Transfer of Ku86 RNA antisense decreases the radioresistance of human fibroblasts.
Marangoni E; Le Romancer M; Foray N; Muller C; Douc-Rasy S; Vaganay S; Abdulkarim B; Barrois M; Calsou P; Bernier J; Salles B; Bourhis J
Cancer Gene Ther; 2000 Feb; 7(2):339-46. PubMed ID: 10770645
[TBL] [Abstract][Full Text] [Related]
12. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.
Kuo CC; Liu JF; Chang JY
J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022
[TBL] [Abstract][Full Text] [Related]
13. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes.
Shao RG; Cao CX; Zhang H; Kohn KW; Wold MS; Pommier Y
EMBO J; 1999 Mar; 18(5):1397-406. PubMed ID: 10064605
[TBL] [Abstract][Full Text] [Related]
14. The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication.
Barrows LR; Holden JA; Anderson M; D'Arpa P
Mutat Res; 1998 Aug; 408(2):103-10. PubMed ID: 9739812
[TBL] [Abstract][Full Text] [Related]
15. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
16. End-joining deficiency and radiosensitization induced by gemcitabine.
van Putten JWG ; Groen HJM ; Smid K; Peters GJ; Kampinga HH
Cancer Res; 2001 Feb; 61(4):1585-91. PubMed ID: 11245469
[TBL] [Abstract][Full Text] [Related]
17. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
18. The non-homologous end-joining pathway is not involved in the radiosensitization of mammalian cells by heat shock.
Dynlacht JR; Bittner ME; Bethel JA; Beck BD
J Cell Physiol; 2003 Sep; 196(3):557-64. PubMed ID: 12891712
[TBL] [Abstract][Full Text] [Related]
19. DNA strand break rejoining defect in xrs-6 is complemented by transfection with the human Ku80 gene.
Ross GM; Eady JJ; Mithal NP; Bush C; Steel GG; Jeggo PA; McMillan TJ
Cancer Res; 1995 Mar; 55(6):1235-8. PubMed ID: 7882315
[TBL] [Abstract][Full Text] [Related]
20. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
